Cargando…

Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II

To overcome poor pharmacokinetics and toxicity of triptolide (TPL), a natural compound that exhibits potent anticancer activities, we developed a novel antibody-drug conjugate (ADC) to specifically deliver TPL to epidermal growth factor receptor (EGFR)-overexpressing non-small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Keqiang, Ma, Yuelong, Guo, Yuming, Sun, Ting, Wu, Jun, Pangeni, Rajendra P., Lin, Min, Li, Wendong, Horne, David, Raz, Dan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394741/ https://www.ncbi.nlm.nih.gov/pubmed/32775615 http://dx.doi.org/10.1016/j.omto.2020.07.001

Ejemplares similares

Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression
por: Sun, Ting, et al.
Publicado: (2022)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts
por: Sreeranganathan, Maya, et al.
Publicado: (2017)

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
Publicado: (2019)

G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer
por: Pangeni, Rajendra P., et al.
Publicado: (2020)

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
por: Zhang, Lianhai, et al.
Publicado: (2013)

Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer
por: Zhang, Keqiang, et al.
Publicado: (2019)

Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles
por: Qian, Yichun, et al.
Publicado: (2014)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

Triptolide (TPL) Inhibits Global Transcription by Inducing Proteasome-Dependent Degradation of RNA Polymerase II (Pol II)
por: Wang, Ying, et al.
Publicado: (2011)

Inhibition of RNA polymerase III transcription by Triptolide attenuates colorectal tumorigenesis
por: Liang, Xia, et al.
Publicado: (2019)

Novel Carboxylated Chitosan-Based Triptolide Conjugate for the Treatment of Rheumatoid Arthritis
por: Zhang, Lan, et al.
Publicado: (2020)

A Glucose-Triptolide Conjugate Selectively Targets Cancer Cells under Hypoxia
por: Datan, Emmanuel, et al.
Publicado: (2020)

In vivo antitumor effects of carboxymethyl chitosan-conjugated triptolide after oral administration
por: Zeng, Huahui, et al.
Publicado: (2020)

EGFR Suppression Inhibits the Sphere Formation of MCF7 Cells Overexpressing EGFR
por: Novak, D. D., et al.
Publicado: (2023)

Autophagy Upregulation and Apoptosis Downregulation in DAHP and Triptolide Treated Cerebral Ischemia
por: Yang, Yang, et al.
Publicado: (2015)

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
por: Goulet, Dennis R., et al.
Publicado: (2022)

Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy
por: Tseng, Shih-Heng, et al.
Publicado: (2015)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Comparison of Conjugation Strategies of Cross-Bridged Macrocyclic Chelators with Cetuximab for Copper-64 Radiolabeling and PET Imaging of EGFR in Colorectal Tumor-Bearing Mice
por: Zeng, Dexing, et al.
Publicado: (2014)

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using (47)Sc-conjugated cetuximab
por: Kim, Da-Mi, et al.
Publicado: (2023)

Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells
por: Zhang, Keqiang, et al.
Publicado: (2023)

The effect of near-infrared fluorescence conjugation on the anti-cancer potential of cetuximab
por: Yun, Ji Young, et al.
Publicado: (2018)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab
por: Liu, Qizhi, et al.
Publicado: (2021)

EP2-PKA signaling is suppressed by triptolide in lipopolysaccharide-induced microglia activation
por: Zhang, Ting, et al.
Publicado: (2015)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Makabe, Koki, et al.
Publicado: (2021)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells
por: FUKUDA, KAZUMASA, et al.
Publicado: (2011)

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer
por: Yang, Guang, et al.
Publicado: (2021)

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
por: Greene, Michelle K., et al.
Publicado: (2020)

Cetuximab Conjugated with Octreotide and Entrapped Calcium Alginate-beads for Targeting Somatostatin Receptors
por: Abdellatif, Ahmed A. H., et al.
Publicado: (2020)

Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW
por: Amini, Abolfazl, et al.
Publicado: (2022)

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
por: Avvakumova, S., et al.
Publicado: (2019)

Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer
por: Nowsheen, Somaira, et al.
Publicado: (2011)

Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin
por: Wu, Xia, et al.
Publicado: (2022)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Reade, Chad A, et al.
Publicado: (2009)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab
por: Liu, Shujie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cbc4m9c37ursdi17ib4ti09kdg